Why clinical trials are inefficient and why it matters

Clinical trials are currently slow and costly, which negatively impacts the pharmaceutical industry and limits the number of treatments that reach patients and the speed at which they arrive. Adam Kroetsch at Policy and Practice emphasizes the need for clinical trial abundance, suggesting that less expensive and more abundant trials would lead to more treatments and cures.